Bioreactor-based mass production of human iPSC-derived macrophages enables immunotherapies against bacterial airway infections.

ABSTRACT: The increasing number of severe infections with multi-drug-resistant pathogens worldwide highlights the need for alternative treatment options. Given the pivotal role of phagocytes and especially alveolar macrophages in pulmonary immunity, we introduce a new, cell-based treatment strategy to target bacterial airway infections. Here we show that the mass production of therapeutic phagocytes from induced pluripotent stem cells (iPSC) in industry-compatible, stirred-tank bioreactors is feasible. Bioreactor-derived iPSC-macrophages (iPSC-Mac) represent a highly pure population of CD45⁺CD11b⁺CD14⁺CD163⁺ cells, and share important phenotypic, functional and transcriptional hallmarks with professional phagocytes, however with a distinct transcriptome si

SUBMITTER: Ackermann M 

PROVIDER: S-EPMC6269475 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature